PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩500 per share · Prices as of the 2026-10-02 close
Chong Kun Dang's top line is being driven by in-licensed products such as Wegovy and Eylea, while rising cost ratios and expanding R&D spending keep profitability at a low, defensive level.
2025 revenue rose to KRW 1,692.4bn but operating margin fell to 4.8%, and low margins continued through both Q1 and Q2 of 2026.
In-licensed products such as Wegovy, Fexuclue, Godex and Eylea are driving sales growth, but their high cost ratio limits profit contribution.
The R&D-to-sales ratio has climbed into the high single digits to low double digits, and the debt ratio has also risen alongside continued investment in the Baegot research complex.
Two policy variables are pending in the second half: the re-certification review for innovative pharmaceutical company status and the efficacy review of Gliatilin (choline alfoscerate).
The drug pipeline, including CKD-510 licensed to Novartis, is cited as a mid- to long-term growth driver, but its near-term earnings contribution remains limited.
Chong Kun Dang operates a business model combining self-developed prescription drugs with products in-licensed from global pharmaceutical companies.
Recent revenue growth has been driven by co-marketed and in-licensed items including the obesity treatment Wegovy (Novo Nordisk), the GERD treatment Fexuclue (Daewoong Pharmaceutical), the liver disease treatment Godex (Celltrion Pharm), and the ophthalmic treatment Eylea.
However, these in-licensed products, while quickly expanding sales scale and boosting utilization of the sales network, are unlikely to guarantee high operating margins. As of Q1 2026, in-licensed items were estimated to account for more than 45% of total revenue.
The company's flagship self-developed product, the dementia and cognitive-function drug Gliatilin, uses choline alfoscerate, with rights acquired from originator Italfarmaco in 2016.
In R&D, the company's new drug research institute focuses on oncology, neurology, immunology and metabolic disease areas to pursue innovative drug development.
The pipeline includes the Novartis-licensed HDAC6 inhibitor CKD-510, alongside the dyslipidemia candidate CKD-508, solid tumor candidate CKD-512, non-small cell lung cancer candidate CKD-702, and the ADC-based oncology candidate CKD-703, all in Phase 1 or Phase 1/2a.
Competitively, the company sits alongside Hanmi Pharmaceutical, Yuhan, Daewoong and GC Biopharma among Korea's top pharmaceutical firms, though its high share of in-licensed product sales gives it a different profit structure compared with peers more centered on proprietary new drugs.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩434.8B | ₩23.6B | 5.4% |
| 2025Q3 | ₩429.8B | ₩21B | 4.9% |
| 2025Q4 | ₩426.8B | ₩23.5B | 5.5% |
| 2026Q1 | ₩447.8B | ₩14.1B | 3.1% |
| 2026Q2 | ₩478.5B | ₩18.6B | 3.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩1.5T | ₩109.9B | ₩81B | 7.4% | 13.0% | 81.1% |
| 2023 | ₩1.7T | ₩246.6B | ₩212.5B | 14.8% | 26.1% | 71.9% |
| 2024 | ₩1.6T | ₩99.5B | ₩109.1B | 6.3% | 12.2% | 62.7% |
| 2025 | ₩1.7T | ₩80.6B | ₩77.5B | 4.8% | 7.7% | 78.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
On an annual basis, revenue moved from KRW 1,488.3bn in 2022 to KRW 1,669.4bn in 2023, KRW 1,586.4bn in 2024, and KRW 1,692.4bn in 2025, growing modestly with some fluctuation. Operating margin, however, jumped from 7.4% in 2022 to 14.8% in 2023 before falling back to 6.3% in 2024 and 4.8% in 2025.
The elevated 2023 margin is interpreted as reflecting one-off factors including the Novartis licensing deal, followed by two consecutive years of margin normalization and decline. Owners' net income also rose to KRW 212.5bn in 2023 before contracting to KRW 109.1bn in 2024 and KRW 77.5bn in 2025.
On a quarterly basis, revenue was KRW 434.8bn with operating profit of KRW 23.6bn in Q2 2025, while Q4 2025 posted revenue of KRW 426.8bn and operating profit of KRW 23.5bn; notably, net income of KRW 26.6bn exceeded operating profit that quarter, suggesting the presence of non-operating factors.
Moving into 2026, Q1 revenue reached KRW 447.8bn with operating profit of KRW 14.1bn (margin in the low-3% range), and Q2 revenue reached KRW 478.5bn with operating profit of KRW 18.6bn — revenue grew while the operating margin remained at a low level.
R&D expenses rose from KRW 157.4bn (9.92% of sales) in 2024 to KRW 185.8bn (10.98%) in 2025, and Q1 2026 R&D spending of KRW 50.0bn pushed the ratio to 11.17%, sharply up from Q1 2025's KRW 38.8bn (9.69%).
On a first-half basis, R&D spending increased by KRW 30.4bn year-on-year while consolidated operating profit fell by only KRW 3.4bn, showing that the increase in R&D investment far outpaced the decline in profit.
Among Korea's five major pharmaceutical companies, Chong Kun Dang's 2025 operating margin of 4.76% trailed Hanmi Pharmaceutical (16.66%), Daewoong Pharmaceutical (12.53%) and Yuhan (4.77%), while exceeding GC Biopharma (3.47%), reflecting a relatively low-margin structure.
This gap has been attributed to R&D spending, new drug development costs, and the growing share of in-licensed products.
On the policy front, the Ministry of Health and Welfare implemented a generic drug pricing reform from August 1 that lowers generic prices relative to originator drugs from a maximum of 53.55% to 45%, while innovative pharmaceutical companies retain up to 60% and quasi-innovative companies up to 50%, along with grace periods on stepwise price cuts.
Chong Kun Dang lost its innovative pharmaceutical company status after failing the 2024 re-certification review, but under the revised certification standard, the disqualifying rebate-violation reference point shifted from the "administrative sanction date" to the "violation completion date,
In June 2026, the company finalized a large-scale biopharmaceutical research complex investment in the Baegot district of Siheung; combined with the KRW 94.9bn land acquisition cost from August 2025, the total investment reaches roughly KRW 500bn on top of the announced KRW 392.5bn.
The research complex targets completion in August 2028, making further cost increases unavoidable in the near term, with the key watch point being how much of the capex and R&D spending operating cash flow can absorb over the next two years.
On the policy calendar, the Ministry of Health and Welfare will accept applications for innovative pharmaceutical company certification from August 18 to September 18, with the review expected to conclude by year-end.
Chong Kun Dang plans to present R&D achievements including CKD-510 as supporting evidence for this re-certification attempt.
On the pipeline front, the c-Met-targeted ADC candidate CKD-703 received FDA IND approval for a Phase 1/2a trial in July and is now in trials in the United States, while the oral obesity drug candidate CKD-514 is expected to enter Phase 1 trials in the second half of 2026.
CKD-510, licensed to Novartis, is in a Phase 2 trial for atrial fibrillation expected to conclude in the second half of 2027, making the timing of data readouts an important point to monitor.
Meanwhile, Kiwoom Securities assessed that the Gliatilin efficacy review is expected during the second half, and that depending on the outcome, second-half earnings could not be ruled out from being revised downward.
Chong Kun Dang's net income rose sharply in 2023 before contracting for two consecutive years, and even in 2026 quarterly results have shown solid revenue growth accompanied by persistently low margins.
Against this earnings backdrop, the market's price-to-book multiple has tended to trade at a discount to net asset value, which appears to reflect the earnings normalization process following the licensing-driven profit spike of 2023.
Dividends have been paid consistently each year, though the payout level itself is not large.
Kiwoom Securities analyst Hye-min Heo stated in a June 2026 report that "valuation attractiveness is very high, but attention is warranted on whether earnings uncertainty eases, including whether innovative pharmaceutical company certification is obtained." In a July 21, 2026 report, iM Securities lowered its target price for Chong Kun Dang from KRW 120,000 to KRW 90,000, citing an expected Q2 operating profit miss versus market consensus and the need to wait longer for R&D momentum. Overall, sell-side views appear to mix expectations for pipeline value with near-term earnings uncertainty.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
The company continues to add major global products such as Wegovy, Fexuclue, Godex and Eylea, leveraging its sales network for top-line growth. This co-marketing structure helps broaden the revenue base ahead of commercializing self-developed new drugs. Indeed, consolidated H1 2026 revenue posted double-digit growth.
Beyond the Novartis-licensed CKD-510, multiple candidates including CKD-508, CKD-512, CKD-702 and CKD-703 are in clinical stages, giving the pipeline notable breadth. CKD-703 has received FDA IND approval for a Phase 1/2a trial and is proceeding with global clinical trials. Several brokerages have separately assessed CKD-510's pipeline value, reflecting market interest.
Under the revised innovative pharmaceutical company certification standard, the criteria for rebate-related disqualification have been eased, raising assessments that Chong Kun Dang's chances of re-certification are higher than before. The R&D ratio requirement is also comfortably met by the company. If re-certified, positive changes are expected in terms of price preference and policy support access.
The expanding share of in-licensed products boosts sales but comes with a rising cost ratio, keeping the operating margin at a low level. The 2025 operating margin of 4.8% ranks on the lower end among Korea's top pharmaceutical companies. Analysts expect this cost burden to persist for the time being.
With the Baegot research complex investment overlapping with expanding R&D spending, the debt ratio rose from 62.7% in 2024 to 78.9% in 2025. In H1 2026, both the debt ratio and net borrowings are understood to have increased further.
Since the research complex investment continues through 2028, the financial burden is unlikely to ease in the near term.
Depending on the outcome of the Ministry of Food and Drug Safety's efficacy review of choline alfoscerate (Gliatilin), an obligation to return prescription revenue could arise.
Chong Kun Dang has already reflected a related refund liability on its financial statements, but the final decision timing and scale remain uncertain. Innovative pharmaceutical company certification is also a variable that has not yet been confirmed.
Generic pricing reform and innovative pharmaceutical company certification status directly affect drug pricing levels. Exclusion from certification could disadvantage the company in new drug price preference and policy support access.
The choline alfoscerate efficacy review outcome also carries the financial risk of prescription revenue clawback.
As long as the share of in-licensed products continues to expand, cost ratio pressure could persist. The pace of R&D expense growth significantly exceeds the decline in operating profit, meaning there is no clear near-term momentum for profit improvement. The timing of margin recovery is likely to depend on the pace of pipeline commercialization.
Large-scale facility investment such as the Baegot research complex, continuing through 2028, is driving up the debt ratio and net borrowings. If operating cash flow fails to sufficiently absorb capex and R&D spending, the need for additional funding could arise. This is why financial soundness indicators warrant continued monitoring going forward.
The application window for innovative pharmaceutical company certification closes. Whether Chong Kun Dang applies and the R&D evidence it submits (such as CKD-510) will offer an early clue on re-certification prospects.
The Ministry of Food and Drug Safety's efficacy review outcome for choline alfoscerate (Gliatilin) is expected to be announced. It will be important to check whether the indication is retained or removed and the scale of any prescription revenue clawback affecting earnings.
The outcome of the innovative pharmaceutical company certification review is expected to be announced by year-end. Whether certification is obtained will affect access to new drug price preference and policy support.
Preliminary Q3 2026 earnings are expected to be disclosed. This will be a point to check whether the growth trend in in-licensed product sales and the trajectory of cost ratios and R&D spending continue.
This is the expected completion timing for the Phase 2 atrial fibrillation trial of Novartis-licensed CKD-510. It will be important to check whether data is released and whether follow-on milestone payments materialize.
Chong Kun Dang continues to grow its top line centered on in-licensed products such as Wegovy and Eylea, but rising cost ratios combined with expanding R&D spending have kept operating margins at a low level.
Following the sharp profit increase tied to licensing activity in 2023, results normalized and contracted over the following two years, and in H1 2026 revenue grew while profit stagnated.
Investment in the Baegot research complex and a rising R&D ratio are factors adding to financial burden, reflected in the debt ratio climbing from 62.7% in 2024 to 78.9% in 2025.
In the second half, two policy variables — the innovative pharmaceutical company certification review and the choline alfoscerate efficacy review — could further affect earnings and financial structure.
At the same time, the new drug pipeline, including CKD-510, is cited as central to the mid- to long-term growth story, though more time is needed before clinical data and commercialization materialize.
Ultimately, near-term earnings direction appears tied to the cost structure of in-licensed products and the outcome of policy events, while the mid- to long-term direction depends on pipeline clinical progress.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.